NCT04805060 - A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 23, 2021

Primary Completion Date

December 12, 2021

Study Completion Date

December 12, 2025

Conditions

Terminal Malignant Tumors

Interventions

DRUG

TQB2858 injection

TQB2858 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2858 is diluted with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.

Trial Locations (1)

130000

RECRUITING

Jinlin Cancer Hospital, Changchun